How PD-L1 Biomarker Test Results Impact Clinical Management of Lung Cancer

Geoffrey R. Oxnard, MD; Lauren L. Ritterhouse, MD, PhD

Video Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library

Drs. Goeffrey Oxnard and Lauren Ritterhouse review how the results of PD-L1 testing influence the choices in first- or second-line immunotherapy or combination immunochemotherapy in patients with squamous or non-squamous non-small-cell lung cancer.

April 14, 2015

CancerTYPE ID in the Clinic

Dr. Boccia describes cases in which he uses CancerTYPE ID in his clinical practice.

October 10, 2016

Immunotherapy’s Role in Treating Hormone Receptor–Positive Diseases

Dr Thomas Bachelot discusses the potential for incorporating immunotherapy into the treatment of patients with hormone receptor–positive diseases but notes that the current data are weak, and further studies are needed to get a better sense of the viability of this treatment option.